Accelerate Brain Cancer Cure Announces its 2006 Project Award Recipients

Terri S. Armstrong,
D.S.N. M.D.

Anderson Cancer Center

Gauging Impact of Treatment on Symptoms, Health Related Quality of Life and Neurocognitive Function in Patients with Primary Brain Tumors (Co-funded with the Tug McGraw Foundation)


Keith Rich, M.D.
Washington University

Transglutaminase 2 Inhibitor, KCC009, Sensitizes Glioblastomas to chemotherapy

Martin Brown, Ph.D.
Stanford University
Sensitization of Brain Tumors to Radiotherapy

John Sampson,
M.D., Ph.D.

Duke University
Inactivation of Regulatory T-cells to Enhance Immunotherapy Against Cytomegalovirus Antigens in Glioblastoma Multiforme


Santosh Kesari,
M.D., Ph.D.

Cancer Institute

Notch Inhibition in Malignant Gliomas


Qing-Bai She, Ph.D.
Memorial Sloan-Kettering Cancer Center

Development of Therapeutic Strategies for the Inhibition of PI3K/Akt Kinase-Mediated Signaling Pathways in Glioblastoma


Ingo Mellinghoff, M.D.
University of California Los Angeles

Developing Biomarkers for Oncogenic EGFR signaling in Glioblastoma

Al Yung, M.D.
M.D. Anderson

Cancer Center

Evaluation of small molecule inhibitors of the PI3K/Akt pathway


Since its inception, Accelerate Brain Cancer Cure has committed funding to advance translational research across a broad range of promising treatment strategies for brain cancer. This year, Accelerate Brain Cancer Cure has funded more than $700,000 in Project Award grants. “The reviewers had a tough job to select from a formidable pool of candidates and we are truly excited to announce the 2006 Project Award Recipients and to follow the impact of their science over the upcoming year,” stated Dr. David Agus, Accelerate Brain Cancer Cure scientific advisor.

Accelerate Brain Cancer Cure Project Awards are one-year awards to fund translational research projects that have a clear development path and potential for meaningful improvement in treatment outcomes for brain cancer patients in the near term. In 2006, Accelerate Brain Cancer Cure identified four priority areas for funding awards with the highest potential for immediate impact in the field of brain cancer research. These priorities included:

  • Development of molecular targeted therapeutics for brain cancer (with emphasis placed on studies that will lead to clinical trials within 18 months);
  • Non-invasive diagnostic and prognostic biomarkers of disease status and response to therapy in glioma (includes serological biomarkers, anatomic/physiologic imaging);
  • Mechanism of action of bevacizumbab-based therapies in glioma; and
  • Studies targeting quality of life/support of care in patients with brain cancer.

"Our 2006 awardees are leaders in brain cancer researcher and their projects are promising, exciting, and fit well within the scope of the Accelerate Brain Cancer Cure focus," added Accelerate Brain Cancer Cure scientific programs manager, Dr. Joanne Tremblay Salcido.

To learn more about individual research projects,
please visit our website or click on the award recipient links

“After rigorous evaluation and deliberation by our team of reviewers, Accelerate Brain Cancer Cure is pleased to have selected eight recipients whose work holds near-term potential to improve the lives of those with brain cancer and will drive us closer to finding a cure.”
Dr. David Agus

Congratulations to the 2006 Accelerate Brain Cancer Cure Project Award Recipients!





For questions, comments, or if you know of someone who would like to receive an electronic copy of Advance, please send and email to or contact Lindsey Stetson at 202.419.3140.

If you would like to be removed from our distribution list, please send an email to:

1717 Rhode Island Ave NW | Suite 700 | Washington, DC 20036
Phone: 202/419-3140 | Fax: 202/419-3141 | Email: |